Abstract
For the presentation of peptide antigens to cytotoxic CD8+ T lymphocytes of the immune system, the expression of human leukocyte antigen (HLA) class I molecules on the cell surface is necessary. There is increasing evidence that surface HLA class I antigen expression is altered in a variety of human tumours by either loss or down-regulation of these molecules, which may be a strategy for evasion of immunosurveillance by malignant cells. This study has examined the expression of HLA class I molecules in head and neck squamous cell carcinoma (HNSCC) specimens by immunohistochemistry, using a wide panel of antibodies directed against allele-specific as well as monomorphic determinants of these molecules. The expression of TAP proteins, HLA-DR and the co-stimulatory molecule ICAM-1 were also studied. In addition, the expression of the tumour-associated antigens (TAA) p53 and MAGE genes was determined. Aberrant allelic expression of HLA class I antigens was detected in 17 out of 34 (50%) of the specimens stained, whereas HLA class I expression determined by W6/32 staining was found to be heterogeneous in only 2 out of 34 (6%) cases. Decreased expression of ICAM-1 was observed in 12 out of 34 (35%) tumour specimens and de novo expression of HLA-DR (HLA class II) by carcinoma cells in 13 out of 34 (38%) cases. Aberrant expression of HLA class I antigens was frequently observed in cases in which MAGE genes and p53 overexpression were detected. The altered expression of these immunomodulatory molecules in HNSCC may affect prognosis and has important implications for peptide-based immunotherapy strategies for these patients.
Highlights
34 head and neck squamous cell carcinoma tissue specimens were available for use
Complete loss of human leukocyte antigen (HLA) class I molecules by tumour cells was not observed in this group of samples
A lower frequency of loss of W6/32 positivity was found in this study compared with previous studies on head and neck squamous cell carcinoma (HNSCC) and HLA class I expression (Esteban et al, 1989; Houck et al, 1990; Mattijsen et al, 1991), which may be accounted for by differences in the tumour samples used, the high frequency of aberrant allelic expression detected implies that previous studies on HLA class I expression using antibodies directed against monomorphic determinants of these molecules may be underestimates
Summary
The aims of this study were to examine HLA class I allele expression by immunohistochemistry in frozen HNSCC specimens using a wide panel of antibodies obtained from the HLA and Cancer Committee of the 12th International Histocompatibility Workshop and Conference
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
